This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record.
1. Trial at a Glance
CAST, the Cardiac Arrhythmia Suppression Trial, is registered as a completed phase 3 randomized, double-masked study with a primary purpose of prevention. The registry identifies encainide, flecainide, and moricizine as the interventions and lists a cardiovascular disease population encompassing coronary disease, sudden cardiac death, heart arrest, heart diseases, myocardial infarction, myocardial ischemia, and ventricular arrhythmia.
| Feature | CAST |
|---|---|
| Official title | Cardiac Arrhythmia Suppression Trial (CAST) |
| Phase | Phase 3 |
| Status | COMPLETED |
| Start date | 1986-08 |
| Allocation | RANDOMIZED |
| Masking | DOUBLE |
| Primary purpose | PREVENTION |
| Lead sponsor | National Heart, Lung, and Blood Institute (NHLBI) |
| Sponsor type | NIH |
| Interventions | encainide; flecainide; moricizine |
| Enrollment | Not reported in the registry record |
2. Clinical Question
The registry frames CAST as a phase 3 prevention study within a broad cardiovascular disease setting. Its listed conditions include cardiovascular diseases, coronary disease, death, sudden, cardiac, heart arrest, heart diseases, myocardial infarction, myocardial ischemia, and ventricular arrhythmia.
Population
The registry associates the study with cardiovascular disease, coronary disease, sudden cardiac death, heart arrest, heart diseases, myocardial infarction, myocardial ischemia, and ventricular arrhythmia. A more specific participant eligibility description is not reported in the registry fields.
Intervention
The registry identifies three drug interventions: encainide, flecainide, and moricizine.
Comparator
A comparator or control intervention is not identified in the registry fields in the ClinicalTrials.gov record.
Primary question
The record establishes prevention as the primary purpose, but it does not contain a registered primary endpoint or a specific primary statistical hypothesis.
3. Trial Design
Intervention structure
Encainide
- Drug intervention
- Registry does not report an assignment ratio in the ClinicalTrials.gov record
- Registry does not report a dose or schedule in the ClinicalTrials.gov record
Flecainide
- Drug intervention
- Registry does not report an assignment ratio in the ClinicalTrials.gov record
- Registry does not report a dose or schedule in the ClinicalTrials.gov record
Moricizine
- Drug intervention
- Registry does not report an assignment ratio in the ClinicalTrials.gov record
- Registry does not report a dose or schedule in the ClinicalTrials.gov record
Randomized, double-masked prevention study
- Phase 3
- Randomized allocation
- Double masking
- Primary purpose: prevention
4. Endpoints
| Endpoint field | Registry record | Statistical implication |
|---|---|---|
| Registered primary endpoints | None reported | No primary endpoint-specific confirmatory analysis can be identified from the record. |
| Endpoint definition | Not reported | The event or measurement definition is not specified. |
| Endpoint time frame | Not reported | No prespecified assessment window is identified. |
| Primary endpoint hierarchy | Not reported | No hierarchy among multiple primary endpoints is identified. |
5. Statistical Methodology
The registry establishes a randomized and double-masked phase 3 prevention design but does not post statistical analyses or registered primary endpoints. That distinction is important: a study's design determines how a treatment comparison can be protected from bias, while the endpoint and analysis specification determine exactly what statistical question is tested.
Randomization
Randomization is the principal design mechanism recorded for CAST. In a randomized trial, assignment is determined by the randomization procedure rather than by the investigator's choice. When the randomization procedure is properly implemented, treatment groups can be compared without requiring measured baseline characteristics to explain treatment assignment.
The exact estimand depends on the endpoint, analysis population, follow-up period, and treatment assignment structure. Those details are not specified in the registry fields posted on ClinicalTrials.gov for CAST.
Double masking
Double masking is recorded by the registry. Masking is a design feature intended to reduce the influence of treatment knowledge on conduct, assessment, reporting, or other aspects of trial participation. Its statistical value is greatest when the masking procedure is maintained successfully and when outcome assessment could otherwise be influenced by knowledge of treatment.
Phase 3 inference
A phase 3 designation indicates the stage of clinical development recorded by the registry. It does not, by itself, specify the statistical endpoint, effect measure, sample-size calculation, or hypothesis-testing procedure. Those features must come from the trial's prespecified statistical documentation or registered endpoint information.
Prevention as the primary purpose
The registry classifies the study's primary purpose as prevention. For a prevention study, statistical analysis commonly focuses on whether the intervention changes the occurrence of clinically relevant events over a defined period. Depending on the endpoint definition, appropriate methods could include binary-event comparisons, incidence-rate methods, or time-to-event analysis.
If a prevention endpoint is defined as time until an event, survival analysis estimates the probability of remaining event-free beyond time t. The appropriate method depends on the endpoint definition and censoring rules, neither of which is specified in the registry record.
6. Planned Analysis
The ClinicalTrials.gov record identifies CAST as a randomized, double-masked phase 3 prevention study involving encainide, flecainide, and moricizine. It does not register primary endpoints and does not post statistical analyses. Results have not been posted on ClinicalTrials.gov.
How a randomized prevention endpoint would typically be analysed
The appropriate statistical method would first depend on how the prevention outcome is defined. If the endpoint is a time from randomization to a first event, a time-to-event analysis would generally be appropriate because patients can have different lengths of follow-up and some may not experience the event before observation ends.
A Kaplan-Meier estimator can describe the event-free distribution, while a log-rank comparison can test whether the event-time distributions differ between randomized groups. A Cox proportional-hazards model can provide a hazard ratio when its assumptions and the trial's prespecified analysis support that approach.
If the endpoint instead represents whether an event occurred during a fixed observation period, an analysis based on event proportions could be appropriate. If events can occur repeatedly, an incidence-rate or recurrent-event framework may be needed. The registry record does not identify which of these endpoint structures applies to CAST.
Primary analysis principle
The primary analysis should be tied to the endpoint's prespecified definition rather than selected after observing the data.
Randomized comparison
For efficacy, analysis according to randomized assignment is generally the principal framework because it preserves the treatment comparison created by randomization.
Event-time outcomes
When follow-up differs among participants, time-to-event methods can use information available before censoring rather than reducing follow-up to a simple yes/no outcome.
Model assumptions
A model-based estimate such as a hazard ratio requires interpretation in light of its underlying assumptions and the endpoint's censoring structure.
7. Statistical Methods Explained
Why does randomization matter statistically?
Randomization separates treatment assignment from investigators' and participants' baseline characteristics in expectation. This makes the difference between randomized groups a direct estimate of the causal effect of assignment, subject to adherence, missing data, follow-up, and other features of the trial.
What does double masking add?
Double masking can reduce the possibility that knowledge of treatment assignment changes behavior, clinical management, outcome assessment, or reporting. It therefore complements randomization: randomization addresses treatment allocation, while masking can reduce certain post-allocation sources of bias.
Why can prevention trials require survival analysis?
A prevention event may occur at different times for different participants, while some participants may remain event-free when observation ends. Time-to-event analysis incorporates both the event time and the information available before censoring. It can therefore be more informative than simply counting whether an event ever occurred.
What would a hazard ratio mean if CAST used a time-to-event endpoint?
A hazard ratio would compare the estimated instantaneous event rates between randomized groups under the fitted model. A value below 1 would indicate a lower estimated event hazard in the numerator group, while a value above 1 would indicate a higher estimated event hazard. It would not directly represent a percentage of patients prevented from experiencing the event.
Why is the endpoint definition essential?
The endpoint determines what constitutes an event, when observation begins, when observation ends, and how censoring is handled. Without those definitions, an effect estimate can be numerically precise but clinically ambiguous because the quantity being estimated is not clearly specified.
Why does a phase 3 label not determine the statistical test?
Phase describes the development stage of the study, not the mathematical structure of its endpoint. A phase 3 trial can use different statistical methods depending on whether its primary outcome is binary, continuous, count-based, or time-to-event.
8. Analysis Populations
The registry fields posted on ClinicalTrials.gov for CAST do not specify an intention-to-treat population, per-protocol population, as-treated population, safety population, or other analysis population.
| Analysis population | Registry status | Statistical role |
|---|---|---|
| Intention-to-treat | Not reported | Would ordinarily preserve the randomized treatment comparison for primary efficacy inference. |
| Per-protocol | Not reported | Could describe outcomes among participants meeting protocol-defined treatment requirements if prespecified. |
| As-treated | Not reported | Could classify participants according to treatment actually received, but may weaken the protection provided by randomization. |
| Safety population | Not reported | Would ordinarily be defined according to treatment exposure and safety-reporting rules. |
These populations answer different questions. In a randomized efficacy analysis, preserving the original treatment assignment is usually central to causal interpretation. An exposure-based safety analysis can use a different population because safety is tied to treatment actually received. The precise CAST definitions are not present in the registry record.
9. Missing Data and Censoring
The registry record does not specify missing-data methods, censoring rules, withdrawal handling, or imputation procedures. These details are particularly important if the primary endpoint is measured over time.
Censoring
For a time-to-event endpoint, censoring indicates that the event has not been observed after the participant's last usable follow-up. The analysis must specify when and why censoring occurs.
Missing outcome data
Missing observations can affect estimates when the probability of missingness is related to treatment, prognosis, or the unobserved outcome.
Imputation
An imputation strategy substitutes plausible values for missing observations under explicit assumptions. No imputation method is identified in the registry record.
Sensitivity analysis
When missingness or censoring could materially affect conclusions, sensitivity analyses can examine how inference changes under alternative assumptions.
10. Multiplicity and Multiple Interventions
The registry identifies three drug interventions: encainide, flecainide, and moricizine. It does not specify the assignment structure, primary comparisons, endpoint hierarchy, or multiplicity-adjustment procedure.
This distinction matters statistically. If several interventions are each compared with a common control, or if multiple pairwise comparisons are made, the probability of obtaining at least one statistically significant result can exceed the nominal significance level unless the testing strategy accounts for multiplicity.
The appropriate multiplicity procedure depends on the number and structure of hypotheses, their logical hierarchy, and the prespecified testing strategy. No such procedure is identified in the registry fields posted on ClinicalTrials.gov for CAST.
11. Interim Analysis and Sequential Testing
The registry record posted on ClinicalTrials.gov for CAST does not identify an interim analysis plan, information fractions, stopping boundaries, alpha-spending method, or sequential-testing procedure.
An interim analysis can be statistically useful when a trial needs to evaluate accumulating evidence before its planned completion. However, repeatedly examining unadjusted significance levels can increase the overall type I error rate. A valid group-sequential design therefore prespecifies when interim looks occur and how the significance boundary changes across those looks.
12. Bayesian Methods
No Bayesian statistical method is identified in the registry record posted on ClinicalTrials.gov for CAST. A Bayesian analysis would ordinarily specify prior distributions, a likelihood for the observed endpoint, and a posterior quantity such as the probability that a treatment effect exceeds a clinically relevant threshold.
The posterior distribution combines the statistical model for the observed data with the specified prior distribution. Because no Bayesian model is reported in the registry record, no posterior probability or Bayesian treatment effect is reported here.
13. Safety Analysis Framework
The registry record identifies encainide, flecainide, and moricizine as drug interventions but does not report serious adverse events by arm, adverse-event counts, treatment exposure, or a safety analysis population.
| Safety component | Registry record |
|---|---|
| Serious adverse events by arm | Not reported |
| Adverse-event counts | Not reported |
| Safety analysis population | Not reported |
| Treatment exposure | Not reported |
| Safety endpoint definitions | Not reported |
For a randomized drug trial, safety analysis is conceptually distinct from efficacy analysis. Efficacy is anchored to the randomized comparison, whereas adverse events are related to actual exposure and may require an analysis population defined around treatment received. Exact CAST safety methods would require the relevant statistical or clinical reporting beyond the registry fields reported here.
14. Clinical Interpretation vs Statistical Interpretation
Statistical interpretation
The registry establishes a randomized, double-masked phase 3 prevention design. It does not identify registered primary endpoints or post statistical analyses, so no numerical treatment effect can be interpreted from the registry record.
Clinical interpretation
The registry places the study within cardiovascular disease and ventricular arrhythmia prevention and identifies three antiarrhythmic drug interventions. The record does not provide enough endpoint or outcome information to quantify clinical effects.
15. Limitations
- No registered primary endpoints: the record does not identify the endpoint that defines the principal confirmatory question.
- No posted statistical analyses: ClinicalTrials.gov does not contain statistical-analysis results for the registered study in the ClinicalTrials.gov record.
- No enrollment value: the enrollment field is not reported, so the size of the randomized population cannot be established from this record.
- Incomplete intervention structure: the registry identifies encainide, flecainide, and moricizine but does not specify the treatment-assignment structure in the registry-reported fields.
- No comparator specified: the ClinicalTrials.gov record does not identify a control intervention.
- No endpoint definitions: there is no registered event definition or measurement time frame from which to establish an estimand.
- No analysis population definitions: intention-to-treat, per-protocol, as-treated, and safety populations are not specified.
- No missing-data or censoring rules: the statistical consequences of withdrawal and incomplete follow-up cannot be assessed from the registry record.
- No multiplicity plan: the record does not state how multiple interventions or multiple hypotheses were handled.
- No interim-analysis plan: sequential monitoring and stopping rules are not reported in the registry fields.
16. Why This Trial Matters Statistically
CAST is useful as a statistical teaching case because the registry captures several fundamental elements of randomized clinical-trial design while leaving the endpoint and analysis specification unstated in the available record. That separation illustrates why trial design, estimand definition, and statistical inference must be considered together.
| Concept | How it appears in CAST |
|---|---|
| Randomization | The registry classifies allocation as RANDOMIZED. |
| Masking | The registry classifies the study as DOUBLE. |
| Phase 3 design | The registry identifies the study as Phase 3. |
| Prevention | PREVENTION is recorded as the primary purpose. |
| Multiple interventions | Encainide, flecainide, and moricizine are listed as drug interventions. |
| Endpoint specification | No registered primary endpoints are reported. |
| Effect estimation | No posted statistical analyses are reported. |
| Analysis populations | No specific efficacy or safety populations are reported. |
| Multiplicity | No multiplicity procedure is reported. |
| Interim analysis | No interim-analysis method is reported. |
17. From Trial Design to Statistical Estimand
A useful way to understand a clinical trial statistically is to move from the design question to the estimand. The registry establishes randomization, masking, purpose, and interventions. A complete estimand would then require a clearly defined population, treatment comparison, endpoint, and time frame.
Population
Who is being compared must be defined through eligibility criteria and the analysis population.
Treatment
The intervention strategy must specify what each randomized group receives and how treatment assignment is structured.
Endpoint
The outcome must specify exactly what constitutes success, failure, or an event.
Time
The assessment window determines whether the analysis is a fixed-time comparison or a time-to-event analysis.
These components are not interchangeable. For example, knowing that a study is randomized does not identify whether the appropriate effect measure is a risk ratio, risk difference, odds ratio, rate ratio, or hazard ratio. That choice follows from the endpoint and estimand.
18. Interpreting a Future Treatment Effect
If a formal analysis were available, the most informative presentation would separate the effect estimate from its uncertainty and from its clinical interpretation. The effect measure should first be named, followed by the corresponding confidence interval and statistical test where applicable.
An effect estimate quantifies the observed difference or ratio between randomized treatment groups. Its interpretation depends on the scale: a risk difference, risk ratio, odds ratio, rate ratio, and hazard ratio are different statistical quantities.
A confidence interval describes statistical uncertainty around an estimated parameter under the specified sampling and modeling framework. It does not describe the range of effects experienced by individual participants.
A P-value addresses the compatibility of the observed data with a specified null hypothesis under the statistical model. It does not measure the magnitude, clinical importance, or probability that a treatment works.
For a time-to-event analysis, interpretation would also require attention to censoring and the proportional-hazards assumption if a Cox model were used. For multiple treatment comparisons, the interpretation would additionally depend on the prespecified multiplicity strategy.
19. Longitudinal Trial History
Study start
The ClinicalTrials.gov record lists 1986-08 as the study start date.
Clinical development stage
The registry classifies CAST as a phase 3 study with prevention as its primary purpose.
Registry status
The ClinicalTrials.gov record lists the study status as COMPLETED.
20. What the Registry Record Establishes
| Question | What can be established |
|---|---|
| What was the study called? | Cardiac Arrhythmia Suppression Trial (CAST). |
| What was the phase? | Phase 3. |
| How was treatment allocated? | Randomized. |
| Was the study masked? | Double. |
| What was its primary purpose? | Prevention. |
| Which interventions are listed? | Encainide, flecainide, and moricizine. |
| Who sponsored the study? | National Heart, Lung, and Blood Institute (NHLBI). |
| What is the sponsor type? | NIH. |
| When did the study start? | 1986-08. |
| Was enrollment reported? | No enrollment value is reported. |
| Are primary endpoints registered? | No registered primary endpoints are reported. |
| Are statistical analyses posted? | No posted statistical analyses are reported. |
21. A Practical Statistical Reading of CAST
The strongest statistical information contained in the registry record is therefore about design, rather than outcome estimation. Randomization establishes the intended comparison structure. Double masking addresses a different class of potential bias. The prevention designation identifies the broad purpose. The intervention list identifies the drugs being studied.
What is missing is equally important for statistical interpretation: the primary endpoint, endpoint time frame, comparator, enrollment, analysis population, effect measure, uncertainty estimate, hypothesis test, and missing-data strategy are not reported in the ClinicalTrials.gov record. Without those components, an observed numerical result could not be mapped reliably to a prespecified estimand.
22. Sources
- ClinicalTrials.gov: NCT00000526 — Cardiac Arrhythmia Suppression Trial (CAST).
Continue through the Clinical Biostats knowledge graph
Clinical trial design connects randomized allocation, masking, endpoint definition, estimands, statistical models, and interpretation of uncertainty.
23. Record Summary
CAST is registered as a completed phase 3 randomized, double-masked prevention study sponsored by the National Heart, Lung, and Blood Institute. The registry identifies encainide, flecainide, and moricizine as drug interventions and associates the study with cardiovascular disease, coronary disease, sudden cardiac death, heart arrest, heart diseases, myocardial infarction, myocardial ischemia, and ventricular arrhythmia.
From a statistical perspective, the record provides a clear example of why trial design information alone is not sufficient to define an estimand or interpret an outcome. No registered primary endpoints or posted statistical analyses are reported in the ClinicalTrials.gov record. A complete statistical interpretation therefore begins with the documented randomized and double-masked design while recognizing that the endpoint, comparator, analysis population, effect measure, and formal inference are not specified in the registry record.